Ectopic cushing's syndrome caused by a pulmonary acth-secreting tumor in a patient treated with octreotide;Síndrome de Cushing ectópico causado por um tumor pulmonar secretor de ACTH em tratamento com octreotide

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 56, Issue 7, 2012, Pages 461-464

  Rodrigues, Pedro ^a,b   Castedo, José Luís ^a   Damasceno, Margarida ^a   Carvalho, Davide ^a,b  

^a Universidade do Porto   (Portugal)

^b Porto School of Nursing   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; OCTREOTIDE;

ADULT; ARTICLE; CARCINOMA; CASE REPORT; CUSHING SYNDROME; ECTOPIC CORTICOTROPIN PRODUCTION; HUMAN; LUNG TUMOR; MALE; SECRETION (PROCESS);

ACTH SYNDROME, ECTOPIC; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, NEUROENDOCRINE; CUSHING SYNDROME; HUMANS; LUNG NEOPLASMS; MALE; OCTREOTIDE;

EID: 84869074246     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302012000700009     Document Type: Article

References (17)

1. Isidori AM, Lenzi A. Ectopic ACTH syndrome. Arq Bras Endocrinol Metab. 2007;51(8):1217-25.
2. Baylin SB, Mendelsohn G. Ectopic hormone production by tumors: mechanisms involved and the biological and clinical implications. Endocr Rev. 1980;15:752-87.
3. Aron DC, Findling JW, Tyrrell JB. Glucocorticoids and adrenal androgens. In: Gardner DG, Shoback D, editors. Greenspan's Basic and Clinical Endocrinology. 8th ed. New York: McGraw Hill; 2007. p. 346-95.
4. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998;19(5):647-72.
5. Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371-7.
6. Scanagatta P, Montresor E, Pergher S, Mainente M, Bonadiman C, Benato C, et al. Cushing's syndrome induced by bronchopulmonary carcinoid tumours: a review of 98 cases and our experience of two cases. Chir Ital. 2004;56(1):63-70.
7. Ejaz S, Vissilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, et al. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Andersen Cancer Center Experience. Cancer. 2011;117(19):4381-9.
8. Ilias I, Torpy DJ, Pacak N, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005;90(8):4955-62.
9. Stewart PM. Adrenal cortex and endocrine hypertension. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: WB Saunders; 2008. p. 445-537.
10. Beuschlein F, Hammer GD. Ectopic pro-opiomelanocortin syndrome. Endocrinol Metab Clin. 2002;31:191-234.
11. Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci. 2002;970:134-44.
12. Fasshauer M, Lincke T, Witzigmann H, Kluge R, Tannapfel A, Moche M, et al. Ectopic Cushing's syndrome caused by a neuroendocrine carcinoma of the mesentery. BMC Cancer. 2006;6:108.
13. Öberg K. Cancer: antitumor effects of octreotide LAR, a somatostatin analog. Nat Rev Endocrinol. 2010;6(4):188-9.
14. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-63.
15. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757-62.
16. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733-42.
17. Öberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966-73.